Live Breaking News & Updates on Inactive thyroid eye disease patient journey

Horizon Therapeutics plc Announces Data from the TEPEZZA® (teprotumumab-trbw) Phase 4 Clinical Trial in Patients with Chronic/Low CAS Thyroid Eye Disease (TED) to be Presented at the Upcoming Endocrine Society (ENDO) Annual Meeting

TEPEZZA Phase 4 trial results to be shared in an oral presentation on Saturday, June 17 at 3:30 p.m. CT

Two patients will share their real-world experience living with TED and being. | June 5, 2023

Olmsted-county , Minnesota , United-states , Chicago , Illinois , Jeffreyw-sherman , Malini-gupta , Instagram , Duke-university-health-system , European-group-on-grave-orbitopathy , Nasdaq , Linkedin